For FY 2026, the company is targeting up to 10% growth over its 2025 revenue. ・Moderna’s Q1 net product sales rose on ...
In a recent study published in Nature, University of Pennsylvania scientists investigated a novel approach for treating pre-eclampsia, a severe and often life-threatening pregnancy disorder, by using ...
A growing list of editing tools can be used to make small changes to the genetic code, tweaking key nucleotides to address the underlying causes of diseases. But bigger edits are often needed, and ...
Penn Engineers have made a critical breakthrough that bridges a major healthy equity gap for pregnant people with pre-eclampsia, a condition that arises due to insufficient blood flow to the placenta ...
Delivering babies early, when possible, is currently the only way to deal with the common pregnancy complication pre-eclampsia. But the condition has now been successfully treated in mice by ...
Bivalent EABR mRNA boosters broaden neutralizing responses to Omicron subvariants by promoting diverse receptor-binding domain epitope targeting, although antibody responses remain partially shaped by ...
A new study by researchers at the Icahn School of Medicine at Mount Sinai overturns a longstanding assumption about how mRNA vaccines generate immunity, revealing that certain non-immune cells help ...
Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein, is under ...
The United States may be losing its edge in mRNA technology. The technology, which powered life-saving COVID-19 vaccines and is now rocketing new cancer therapeutics forward, will soon undergo a ...
Silencing mRNA expression in dendritic cells did not impair T‑cell priming, including for SARS‑CoV‑2 antigens, suggesting that cross‑presentation by other cell types is sufficient to initiate immunity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results